ProCE Banner Activity

FAQs: Optimizing the Care of Patients With Relapsed/Refractory MCL

Clinical Thought

In this commentary, international expert faculty address frequently asked questions about the selection and sequencing of BTK inhibitors for patients with relapsed/refractory mantle cell lymphoma.

Released: April 05, 2023



Julie M. Vose

Julie M. Vose, MD, MBA

Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Marco Ladetto

Marco Ladetto, MD

Associate Professor
Dipartimento di Medicina Traslazionale
Università del Piemonte Orientale
Vercelli/Novara/Alessandria, Piedmont, Italy
Director of Hematology Oncology
SCDU Ematologia
AO SS Antonio E Biagio e Cesare Arrigo
Alessandria, Piedmont, Italy

Max Topp

Max Topp, MD

Head of Hematology
Department of Hematology
Universitätsklinikum Würzburg
Würzburg, Germany

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from


Faculty Disclosure

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Caribou, Daiichi Sankyo, Genentech, Kite, Lilly, MEI Pharma, MorphoSys, Pharmacyclics, Seattle Genetics.

Marco Ladetto, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, Amgen, AstraZeneca, EUSA Pharma, Gentili, Gilead/Kite, Incyte, Johnson & Johnson, Jazz, Lilly, Regeneron, Roche.

Max Topp, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Janssen, Kite, Roche.